Interferon beta ( @entity2391 ) is a first-line therapy for @entity15 ( @entity15 ). However, some @entity1 experience a decline in efficacy with continued therapy due to the development of anti- @entity2391 neutralizing antibodies (NAb). We investigated the frequency of NAb cross-sectionally in 846 @entity15 @entity1 who were receiving @entity2391 -1b, @entity2391 -1a im, or @entity2391 -1a sc. The frequency of NAb in @entity1 receiving @entity2391 -1a im was lower (5%) than in @entity1 treated with any other form of @entity2391 (22-35%) (P < 0.0001). Binding antibodies (BAb) were measured in 808 @entity1 . The frequency differed significantly between treatment groups, ranging from 45% ( @entity2391 -1a im) to 88% ( @entity2391 -1b). The proportion of NAb-positive @entity1 within the BAb-positive group differed significantly among treatment groups, ranging between 12% ( @entity2391 -1a im) and 51% ( @entity2391 -1a sc). The median NAb titer from all @entity2391 -1a-treated @entity1 was higher than from @entity2391 -1b-treated @entity1 (446 versus 171 NU/ mL, P = 0.04). Among NAb-positive @entity1 , the frequency of NAb titers > 100 NU/mL was 71% for @entity2391 -1a compared with 58% for @entity2391 -1b (P = 0.04). Except for conflicting data regarding @entity2391 -1a sc, the results are generally consistent with the literature and together with the differing proportion of NAb-positive @entity1 within the BAb-positive group, provide further insight into the immunogenicity of the @entity2391 preparations.

Differing immunogenic potentials of interferon beta preparations in XXXX @entity1 .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity15 :: ('MESH:D009103', 'Disease') :: ['multiple sclerosis', 'MS'] @entity2391 :: ('3456', 'Gene') :: ['IFNbeta']
@entity15 :: (MESH:D009103,Disease) :: ['multiple sclerosis']
